Studies from Columbia University in the Area of Depression Described [Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders]
By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Current study results on Mental Health have been published. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "Although lower levels of omega-3 polyunsaturated fatty acids (PUFAs) are found in major depressive disorder, less is known about PUFA status and anxiety disorders. Medication-free participants with DSM-IV-defined major depressive disorder (MDD), with (n=18) and without (n=41) comorbid DSM-IV anxiety disorders, and healthy volunteers (n=62) were recruited from October 2006 to May 2010 for mood disorder studies at the New York State Psychiatric Institute."
The news correspondents obtained a quote from the research from Columbia University, "Participants were 18-73 years of age (mean age, 35.8 ± 12.6 years). Depression and anxiety severity was assessed using depression and anxiety subscales from the 17-item Hamilton Depression Rating Scale. Plasma PUFAs eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) and the ratio of arachidonic acid (AA; 22:4n-6) to EPA (AA:EPA) were quantified. This secondary analysis employed analysis of variance with a priori planned contrasts to test for diagnostic group differences in log-transformed PUFA levels (logDHA, logEPA, and logAA:EPA). Plasma levels of logDHA (F(2,118)=4.923, p=.009), logEPA (F(2,118)=6.442, p=.002), and logAA:EPA (F(2,118)=3.806, p=.025) differed across groups. Participants with MDD had lower logDHA (t(118)=2.324, p=.022) and logEPA (t(118)=3.175, p=.002) levels and higher logAA:EPA levels (t(118)=-2.099, p=.038) compared with healthy volunteers. Lower logDHA (t(118)=2.692, p=.008) and logEPA (t(118)=2.524, p=.013) levels and higher logAA:EPA levels (t(118)=-2.322, p=.022) distinguished anxious from nonanxious MDD. Depression severity was not associated with PUFA plasma levels; however, anxiety severity across the entire sample correlated negatively with logDHA (r(p)=-0.22, p=.015) and logEPA (r(p)=-0.25, p=.005) levels and positively with logAA:EPA levels (r(p)=0.18, p=.043). The presence and severity of comorbid anxiety were associated with the lowest EPA and DHA levels."
According to the news reporters, the research concluded: "Further studies are needed to elucidate whether omega-3 PUFA supplementation may preferentially alleviate MDD with more severe anxiety."
For more information on this research see: Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders. The Journal of Clinical Psychiatry, 2013;74(7):732-8 (see also Mental Health).
Our news journalists report that additional information may be obtained by contacting J.J. Liu, Institute of Human Nutrition, Columbia University, New York, New York, United States. Additional authors for this research include H.C. Galfalvy, T.B. Cooper, M.A. Oquendo, M.F. Grunebaum, J.J. Mann and M.E Sublette.
Keywords for this news article include: Depression, New York City, United States, Mental Health, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC